Cytotoxic Activity, Topoisomerase I Inhibition and In Silico Studies of New Sesquiterpene-aryl Ester Derivatives of (-) Drimenol

In this study, we aimed to evaluate two sets of sesquiterpene-aryl derivatives linked by an ester bond, their cytotoxic activities, and their capacity to activate caspases 3/7 and inhibit human topoisomerase I (TOP1). A total of 13 compounds were synthesized from the natural sesquiterpene (-)-drimen...

Full description

Bibliographic Details
Main Authors: Ileana Araque, Javiera Ramírez, Rut Vergara, Jaime Mella, Pablo Aránguiz, Luis Espinoza, Waleska Vera, Iván Montenegro, Cristian O. Salas, Joan Villena, Mauricio A. Cuellar
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Molecules
Subjects:
Online Access:https://www.mdpi.com/1420-3049/28/9/3959
Description
Summary:In this study, we aimed to evaluate two sets of sesquiterpene-aryl derivatives linked by an ester bond, their cytotoxic activities, and their capacity to activate caspases 3/7 and inhibit human topoisomerase I (TOP1). A total of 13 compounds were synthesized from the natural sesquiterpene (-)-drimenol and their cytotoxic activity was evaluated in vitro against three cancer cell lines: PC-3 (prostate cancer), HT-29 (colon cancer), MCF-7 (breast cancer), and an immortalized non-tumoral cell line (MCF-10). From the results, it was observed that <b>6a</b> was the most promising compound due to its cytotoxic effect on three cancer cell lines and its selectivity, <b>6a</b> was 100-fold more selective than 5-FU in MCF-7 and 20-fold in PC-3. It was observed that <b>6a</b> also induced apoptosis by caspases 3/7 activity using a Capsase-Glo-3/7 assay kit and inhibited TOP1. A possible binding mode of <b>6a</b> in a complex with TOP1-DNA was proposed by docking and molecular dynamics studies. In addition, <b>6a</b> was predicted to have a good pharmacokinetic profile for oral administration. Therefore, through this study, it was demonstrated that the drimane scaffold should be considered in the search of new antitumoral agents.
ISSN:1420-3049